title: Keratinocyte growth factor induces pancreatic ductal epithelial proliferation.
abstract: Keratinocyte growth factor (KGF) causes a proliferation of pancreatic ductal epithelial cells in adult rats after daily systemic administration for 1 to 2 weeks. Even before the proliferation of intralobular ducts is histologically evident, KGF also induces proliferating cell nuclear antigen expression within the ductal epithelium of intercalated, intralobular, and interlobular ducts. KGF also causes incorporation of 5-bromodeoxyuridine in ductal epithelial cells. Epithelial cell proliferation is histologically most prominent at the level of the intralobular ducts adjacent to and within the islets of Langerhans. Pancreatic ductal proliferation is not histologically apparent in rats sacrificed 7 to 10 days after the cessation of KGF administration. The pancreatic hormones insulin, glucagon, somatostatin, and pancreatic polypeptide are normally distributed within islets that demonstrate intrainsular ductal proliferation. The proliferating ductal epithelium does not show endocrine differentiation as evidenced by the lack of immunoreactivity for pancreatic hormones. KGF is a potent in vivo mitogen for pancreatic ductal epithelial cells.
authors.affiliation: Department of Pathology, University of California, San Diego School of Medicine.
authors.forename: E S
authors.initials: ES
authors.lastname: Yi
authors.forename: S
authors.initials: S
authors.lastname: Yin
authors.forename: D L
authors.initials: DL
authors.lastname: Harclerode
authors.forename: A
authors.initials: A
authors.lastname: Bedoya
authors.forename: N B
authors.initials: NB
authors.lastname: Bikhazi
authors.forename: R M
authors.initials: RM
authors.lastname: Housley
authors.forename: S L
authors.initials: SL
authors.lastname: Aukerman
authors.forename: C F
authors.initials: CF
authors.lastname: Morris
authors.forename: G F
authors.initials: GF
authors.lastname: Pierce
authors.forename: T R
authors.initials: TR
authors.lastname: Ulich
mesh_terms: D000818:Animals; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D004847:Epithelial Cells; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D005260:Female; D051526:Fibroblast Growth Factor 10; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors; D006133:Growth Substances / Q000008:administration & dosage*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D009687:Nuclear Proteins / Q000378:metabolism; D010183:Pancreatic Ducts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D018809:Proliferating Cell Nuclear Antigen; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors
chemical_list: C496455:Fgf7 protein, rat; D051526:Fibroblast Growth Factor 10; D006133:Growth Substances; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors; D001973:Bromodeoxyuridine